• TLC is listed on the Nasdaq Global Market (symbol: TLC)
  • TLC reports positive top-line data from phase II clinical trial of TLC599 in knee osteoarthritis pain
  • Doses first patients in phase I/II trial of TLC590 for postsurgical pain management
  • TLC ranks Top 5% again in Corporate Governance Evaluations
  • TLC178 is designated by the US FDA as an orphan drug for the treatment of soft tissue sarcoma and a rare pediatric disease in the treatment of rhabdomyosarcoma.


  • TLC receives a top 5% ranking in Corporate Governance Evaluation among all TPEx-listed companies.
  • TLC opens subsidiary offices in Australia, Hong Kong, Shanghai and Japan as well as an additional branch office and laboratory facility in Hsinchu City.
  • Ampholipad™ is approved and launched in Taiwan.
  • TLC388 is accepted into the Green Path accelerated development pathway by the CFDA.
  • TLC is listed on the Taipei Exchange (4152:TT).


  • TLC388 obtains orphan drug designation for development in hepatocellular carcinoma (HCC) in both Europe and the United States.
  • TLC establishes subsidiary offices in Leiden, the Netherlands.


  • TLC establishes subsidiary offices in San Francisco, US.
  • TLC’s main office is established in Nangang Software Park, Taipei, Taiwan.
  • Lipo-Dox is approved for treatment of breast cancer, ovarian caner, AIDS-related Kaposi's sarcoma and multiple myeloma.


  • TLC is founded and begins development of Lipo-Dox.